Applied dna announces joint development agreement to integrate linea(tm) ivt platform into cdmo kudo biotechnology's mrna manufacturing workflow

- agreement seeks to leverage linea ivt platform to enable kudo bio to offer a differentiated mrna manufacturing capability with mitigated dsrna and reduced turnaround times - stony brook, ny and needham, ma / accesswire / december 14, 2023 / applied dna sciences, inc. (nasdaq:apdn) (applied dna), a leader in pcr-based dna technologies, and kudo biotechnology (kudo bio), a leading global mrna cdmo offering end-to-end cgmp mrna manufacturing solutions, today announced their entry into a joint development agreement (the "jda") to integrate applied dna's linea™ ivt platform (the "platform") into kudo bio's commercial mrna manufacturing workflows. under the terms of the jda, the companies will seek to optimize mrna quality, yields, and mitigation of contamination by double-stranded rna ("dsrna") in an integrated workflow at manufacturing scale and establish a global co-marketing relationship.
APDN Ratings Summary
APDN Quant Ranking